Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd is an Australia-based company.
The business
Recce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the processes utilized by bacteria and viruses to overcome resistance.
Small Caps Research
No research on Recce Pharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise RCE based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Recce Pharmaceuticals Expands Phase 3 Diabetic Foot Trial With Comparator Arm
Recce expands Phase 3 diabetic foot infection trial with R327G active comparator arm, pursuing non-inferiority vs antibiotics; interim data after 104 patients.
Recce Pharmaceuticals Advances Diabetic Foot Infection Trial to Pivotal Phase 3
Recce Pharmaceuticals expands diabetic foot infection trial to Phase 3, broadening recruitment and adding below-knee ulcers; dual Australia-Indonesia program.
Recce Pharmaceuticals Signs Distribution Agreement for R327 Diabetic Foot Gel across MENA
Recce inks 10-year exclusive MENA licensing deal for R327G diabetic foot gel; upfront fees up to $5m, 30% net sales, Phase III data eyed for year-end approval.
Recce Pharmaceuticals Commences Phase 3 Trial of Topical Gel for Diabetic Foot Infections
Recce Pharmaceuticals (ASX: RCE) has commenced patient dosing for a registrational Phase 3 clinical trial of its RECCE 327 topical gel (R327G) to treat diabetic foot infections (DFI). The company has activated five clinical study sites across one of the world’s largest DFI patient populations in Indonesia, where estimates place the prevalence of diabetes at 20.9 […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.